Diffuse large B-cell lymphoma: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

• All targets
• CD19 42
• CD20 22
• BCL-2 13
• MYC 10
• PD-1 12
• BTK 10
• TP53 7
• PD-L1 3
• CD22 7
• STAT3 0
• CD30 5
• CD47 0
• PI3K 0
• EZH2 1
• LAG-3 0
• ALK 0
• CTNNB1 0
• JAK 0
• STING 0
• BCMA 2
• EGFR 0
• METTL3 0
• mTOR 0
• AKT 0
• CD38 0
• IL-6 0
• JNK 0
• MMP-9 0
• PKM2 0
• PRMT5 0
• TIGIT 1
• TIM-3 0
• ABL1 0
• ARID1A 1
• ATM 0
• BRAF 0
• BRCA1 1
• BRCA2 1
• CCR5 0
• CD40 0
• CDKN2A 0
• CTLA-4 0
• CXCR4 0
• FGFR 0
• FTO 0
• GPX4 0
• HDAC 0
• IL-1 0
• IL-15 0
• MYCN 0
• NLRP3 0
• NOTCH1 1
• PARP 0
• PINK1 0
• PPAR 0
• RAS 0
• SHP2 0
• SIRT1 0
• TERT 0
• TFEB 0

EU-13 is a filter, not a ranking: it only narrows the list.

24 of 52+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  A Study of bbT369 in Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma (NHL)

  NCT05169489· Regeneron Pharmaceuticals· Updated 21 Oct 2025

  “Sponsor Decision”Registry text, quoted unchanged. Source

• Terminated

  Pembrolizumab With Rituximab or Obinutuzumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma

  NCT03401853· University of Washington· Updated 22 Jul 2025

  “Study terminated to end of funding.”Registry text, quoted unchanged. Source

• Terminated

  A Phase 1 Study of ADI-001 in B Cell Malignancies

  NCT04735471· Adicet Therapeutics· Updated 18 Jun 2025

  “Terminated - Halted Prematurely”Registry text, quoted unchanged. Source

• Terminated

  A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma

  NCT03530683· Pfizer· Updated 3 Sept 2024

  “A business decision was made by Pfizer to terminate the study. Termination was not due to any safety concerns, requests from regulatory authorities, changes to the benefit/risk profile or any new concerns regarding the investigational product.”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma

  NCT06091865· Regeneron Pharmaceuticals· Source

• REGN9220 in Combination With Odronextamab in Adult Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphomas (BCNHLs)

  NCT07887750· Regeneron Pharmaceuticals· Source

• A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treated With Other Cancer Therapies

  NCT03888105· Regeneron Pharmaceuticals· Source

• A Study of bbT369 in Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma (NHL)

  NCT05169489· Regeneron Pharmaceuticals· Source

• Study to Investigate the Safety and Tolerability of Odronextamab in Patients With CD20+ B-Cell Malignancies

  NCT02290951· Regeneron Pharmaceuticals· Source

• Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma

  NCT00001337· National Cancer Institute (NCI)· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 9
• Mendelian Randomization Analysis 6
• CRISPR-Cas Systems 1
• Gene Expression Profiling 49
• Sequence Analysis, RNA 1
• Whole Genome Sequencing 2
• Exome Sequencing 3
• Proteomics 4
• Flow Cytometry 7
• Immunohistochemistry 36
• Liquid Biopsy 1
• Circulating Tumor DNA 12
• Xenograft Model Antitumor Assays 30
• Positron-Emission Tomography 15
• Magnetic Resonance Imaging 28
• Machine Learning 11
• Deep Learning 9
• Cohort Studies 15
• Genome-Wide Association Study 4

• Exploring Potential Multi-Target Inhibition Mechanisms of Ganoderma lucidum Against EBV-Mediated DLBCL Using Integrative Bioinformatics, Machine Learning, and Network Pharmacology Approaches.

  J Food Sci, Oct 2026

• A machine learning-derived sarcopenia index is associated with survival and nonrelapse mortality in DLBCL.

  Blood Adv, Sept 2026

• Integrated Clinical-Molecular Risk Stratification in Diffuse Large B-Cell Lymphoma: Machine Learning Survival Analysis.

  JMIR Med Inform, Aug 2026

• Identifying Distinct Molecular Subtypes and Establishing a Prognostic Framework for DLBCL Patients via Multiomics Analysis and Machine Learning Approaches.

  Hum Mutat, Jul 2026

• Machine learning-driven investigation on liquid-liquid phase separation-related prognostic signature in diffuse large B-cell lymphoma.

  Br J Haematol, Jun 2026

• Cell-free chromatin state tracing reveals disease origin and therapy responses.

  Nature, Mar 2026

• Machine learning based on clinical and gene expression data assists in survival prediction and treatment optimization for diffuse large B-Cell lymphoma patients.

  Ann Hematol, Feb 2026

• Integrating machine learning and molecular simulations for the design of potent HDAC2 inhibitors in diffuse large B-cell lymphoma.

  Comput Biol Chem, Feb 2026

• Potential link between dioxin induced progression of diffuse large B-cell lymphoma: New insights from machine learning and in vitro experiments.

  Ecotoxicol Environ Saf, Jan 2026

• Predictive biomarkers validation of CD3+ cell apheresis yield in CAR-T manufacturing for diffuse large B-cell lymphoma: a machine learning approach.

  Sci Rep, Nov 2025

See which targets of this disease your abstract mentions, and go to the people working on them.